Archived market update
This piece is kept for historical context (June 2026). For live quotes and coverage, see the stock hub or the monthly archive.
Looking to trade this stock? See our Interactive Brokers Canada review.
Get APTX alerts:
Apotex Health Corp is making waves on the TSX with a notable gain of 3.89% in the last trading session.
Shares of Apotex Health Corp (APTX.TO) surged by 3.89% yesterday, closing at CA$31.75. This uptick reflects growing investor interest and optimism surrounding the company’s future prospects, particularly in light of its recent moves in the market.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Apotex Health Corp
APTX.TO
APTX.TO
Apotex Health Corp
WealthAwesomeMarket cap
$8.33B
P/E
21.9x
52W high
$40.18
52W low
$26.05
1W change
-3.75%
Analyst Price Targets
Based on analyst covering APTX
Wall Street analysts forecast APTX stock price to rise 13.2% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$40.69
+13.2% Upside
Current Price
C$35.95
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Investor takeaway: Investors should consider the implications of Apotex's rising stock price as a sign of confidence in its upcoming IPO and product launches, which could enhance its market position.
Market Cap Reaches CA$6.95 Billion
Apotex Health Corp's market capitalization stands at CA$6.95 billion, indicating robust investor confidence and a solid foundation for future growth.
Bull case
The positive momentum in Apotex's stock is likely driven by excitement around its upcoming IPO and the recent approval of its ophthalmic product, IHEEZO™, which could significantly broaden its market reach.
Bear case
While the stock is currently performing well, potential investors should stay cautious about market volatility and the challenges that come with launching new products and an IPO.
Recent Developments
Apotex Health Corp has been in the spotlight recently, especially with the filing of its preliminary prospectus for an initial public offering (IPO). This strategic move has generated buzz among investors, contributing to the stock's rise. The company is also expanding its ophthalmic portfolio, having received Health Canada approval for IHEEZO™, a topical anesthetic, which could further enhance its market presence.
Market Performance
In the last trading session, Apotex's stock saw a significant increase of 3.89%, closing at CA$31.75. This performance has brought the company's market cap to approximately CA$6.95 billion, showcasing strong investor confidence. As the company prepares for its IPO, the market is closely watching how these developments will impact its future trajectory.
Looking Ahead
With the upcoming IPO and new product launches on the horizon, Apotex Health Corp appears well-positioned for growth. Investors should keep an eye on how these factors play out in the coming months, as they could significantly influence stock performance and overall market sentiment.
Advertisement
Wealth Awesome Newsroom
The Wealth Awesome Newsroom delivers timely Canadian market updates, earnings, dividends, and stock movers for DIY investors. Coverage is reviewed against public filings and market data feeds.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
